Investment group SV Life Sciences said today it is rebranding to SV Health Investors. The Boston-based company said the new moniker will “better reflect the firm’s longstanding strategy and multi-sector focus.” The investment group said it targets early-stage opportunities in biotechnology, early-stage and revenue stage medical device opportunities and growth equity investments in later-stage businesses in healthcare […]
Healthcare investor SV Life Sciences joined a ‘significant round of growth capital’ for medtech developer Bardy Diagnostics and its Carnation cardiac monitor and arrhythmia detection device. The Charlotte, N.C.-based company’s Carnation ambulatory monitor is a non-invasive P-wave centric ambulatory cardiac monitor and arrhythmia detection device which the company touts as the world’s smallest and lightest […]
SV Life Sciences said it raised $274 million of the $400 million it hopes to put into its 6th fund for investing in healthcare companies. The Boston-based venture capital shop said in a regulatory filing that 24 unnamed investors participated in the round, which began in May 2015. SV Life Sciences, which has some $1.9 billion […]
December 3, 2014 by Brad Perriello
Direct Flow Medical said today that it landed a $32 million funding round for its replacement heart valve technology and tapped a 25-year medical device veteran, Chris Richardson, to lead its commercialization program.
Ximedica said today that SV Life Sciences picked up a majority interest in the Providence, R.I.-based medical device development company from co-founders Stephen Lane and Aidan Petrie for an undisclosed amount.
Correction, Sept. 17, 2013: Due to a reporter’s error, this article originally stated that SafeStitch raised $160 million. The company instead issued $160 million worth of shares as part of its merger with TransEnterix.
"How ‘ya gonna keep ’em down on the farm after they’ve seen Paree?"
Is Facebook really worth two Medtronics (NYSE:MDT)?
MASSDEVICE ON CALL — One year into health care reform, sharp divides remain among Americans about the law along partisan lines, with half of the public unsure about its effects.
Fifty-two percent of Americans say they’re unsure about how the law will affect them, according to a survey of "a nationally representative random sample of 1,202 adults ages 18 and older" conducted by the Kaiser Family Foundation.
A Boston, Mass.-based venture capitalist and former Boston Scientific Corp. (NYSE:BSX) executive is adding his voice to the chorus of medical device stakeholders calling for an overhaul to the way the FDA regulates medical devices.